Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24307956 | 0.84 | LAP3 (0.50) | LAP3FOLH1LMNA | |
| SCHEMBL26871969 | 0.79 | SMN1; SMN2 (0.44) | LAP3ALOX15SMN1; SMN2TSHRLMNA | |
| SCHEMBL24307997 | 0.77 | FOLH1 (0.31) | LAP3FOLH1 | |
| SCHEMBL23635792 | 0.75 | TSHR (0.43) | ALOX15SMN1; SMN2TSHRLMNAHTT | |
| SCHEMBL24308310 | 0.75 | CTSK (0.44) | — | |
| SCHEMBL5281098 | 0.74 | — | — | |
| SCHEMBL18669073 | 0.72 | TSHR (0.37) | FOLH1SMN1; SMN2TSHRLMNA | |
| SCHEMBL3206858 | 0.69 | SMN1; SMN2 (0.40) | LAP3SMN1; SMN2TSHRCYP1A2 | |
| SCHEMBL26940415 | 0.69 | SMN1; SMN2 (0.40) | LAP3SMN1; SMN2TSHRCYP1A2 | |
| SCHEMBL441968 | 0.68 | TSHR (0.46) | ALOX15SMN1; SMN2TSHRLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-11-23 | — | — | US | disclosed |
| WO-2022075486-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | NOTCH1, NOTCH2, HES1 | LAP3 3702/4885ALOX15 971/4885FOLH1 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.